Back to Results
First PageMeta Content
Diarrhea / Gut flora / Ventria Bioscience / Clostridium difficile / Pharmacology / Lactoferrin / Clinical trial / Antibiotic-associated diarrhea / Medicine / Microbiology / Health


NEWS RELEASE Contact: Erik Vogel  Phone: +1 (970) 407‐1239  E‐mail: [removed]   
Add to Reading List

Document Date: 2012-04-04 13:45:18

Open Document

File Size: 178,73 KB

Share Result on Facebook

City

FORT COLLINS / Baltimore / /

Company

Ventria Bioscience / /

Country

United States / /

/

Event

FDA Phase / /

Facility

Johns Hopkins University / High‐Risk Patients FORT / /

/

IndustryTerm

protein product / cell culture media / cost‐effective biologic products / biotherapeutics and products / /

MedicalCondition

VEN100 Reduces Antibiotic‐Associated Diarrhea / inflammatory and antimicrobial properties / antibiotic‐associated diarrhea / C difficile infection / diarrhea / /

MedicalTreatment

antibiotics / /

Organization

Division of Infectious Diseases / Department of Epidemiology / Johns Hopkins University / /

Person

William B. Greenough / Scott Deeter / Michele Bellantoni / Erik Vogel / /

/

Position

study author / chief executive officer / candidate / VEN100 / senior author / clinical director / Division of Geriatric Medicine and Gerontology / professor in the Division / WB / /

Product

ExpressTec / ExpressTec biomanufacturing platform / VEN100 Reduces Antibiotic / /

ProvinceOrState

Maryland / Colorado / /

RadioStation

Laffan AM / /

Technology

biomanufacturing / bioprocessing / biomanufacturing technology / biotherapeutics and products / regenerative medicine / biotherapeutics and / /

URL

www.ventria.com / /

SocialTag